pivotal-therapeutics-inc

Médias

Pivotal Therapeutics cierra financiación

Médias

Pivotal Therapeutics Closes Financing; Receives Over CDN $7.7 Million to Further VASCAZEN® Commercialization

Médias

Pivotal Therapeutics anuncia una Notificación de Aprobación para su formulación 6:1 EPA:DHA

Médias

Pivotal Therapeutics Announces Notice of Allowance for U.S. Patent on its Unique 6:1 EPA:DHA Formulation

Médias

Respaldo positivo de Pivotal Therapeutics Inc. en el European Society of Cardiology Congress 2012

Médias

Pivotal Therapeutics Inc. Generates Positive Feedback at European Society of Cardiology Congress 2012

Médias

Muestra de Pivotal Therapeutics en el European Society of Cardiology Congress 2012

Médias

Pivotal Therapeutics Exhibiting at European Society of Cardiology Congress 2012

Médias

Pivotal anuncia una presentación científica en el 17th World Congress on Heart Disease

Médias

Pivotal Announces Scientific Presentation at the 17th World Congress on Heart Disease Demonstrating Superiority of VASCAZEN™ Unique Formulation